Genetic variability in CYP3A4 and CYP3A5in primary liver, gastric and colorectal cancer patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Genetic variability in CYP3A4 and CYP3A5in primary liver, gastric and colorectal cancer patients ; volume:7 ; number:1 ; day:02 ; month:7 ; year:2007 ; pages:1-7 ; date:12.2007
BMC cancer ; 7, Heft 1 (02.7.2007), 1-7, 12.2007
- Urheber
-
Gervasini, Guillermo
- Beteiligte Personen und Organisationen
-
García-Martín, Elena
Ladero, José M.
Pizarro, Rosa
Sastre, Javier
Martínez, Carmen
García, Monserrat
Diaz-Rubio, Manuel
Agundez, José
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-7-118
- URN
-
urn:nbn:de:1111-2016030344532
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gervasini, Guillermo
- García-Martín, Elena
- Ladero, José M.
- Pizarro, Rosa
- Sastre, Javier
- Martínez, Carmen
- García, Monserrat
- Diaz-Rubio, Manuel
- Agundez, José
- SpringerLink (Online service)
Ähnliche Objekte (12)
CYP3A4 and CYP3A5genotyping by Pyrosequencing
Cross-species variability in lobular geometry and cytochrome P450 hepatic zonation: insights into CYP1A2, CYP2D6, CYP2E1 and CYP3A4
Cross-species variability in lobular geometry and cytochrome P450 hepatic zonation : insights into CYP1A2, CYP2D6, CYP2E1 and CYP3A4
Antivirals and nuclear receptor activation of CYP3A4 and 2B6
Myricetin inhibits CYP3A4, GST, and MRP1 in hepatic cancer cells
Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1and colorectal cancer risk
Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies
CYP3A4 drug metabolism considerations in pediatric pharmacotherapy
Selective expression of KCNA5 and KCNB1 genes in gastric and colorectal carcinoma
Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel
Individualizing simvastatin dose with respect to CYP3A4 activity
Polymorphismen in der Promoter- und Enhancerregion von CYP3A4
CYP3A4 and CYP3A5genotyping by Pyrosequencing
Cross-species variability in lobular geometry and cytochrome P450 hepatic zonation: insights into CYP1A2, CYP2D6, CYP2E1 and CYP3A4
Cross-species variability in lobular geometry and cytochrome P450 hepatic zonation : insights into CYP1A2, CYP2D6, CYP2E1 and CYP3A4
Antivirals and nuclear receptor activation of CYP3A4 and 2B6
Myricetin inhibits CYP3A4, GST, and MRP1 in hepatic cancer cells
Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1and colorectal cancer risk
Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies
CYP3A4 drug metabolism considerations in pediatric pharmacotherapy
Selective expression of KCNA5 and KCNB1 genes in gastric and colorectal carcinoma
Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel
Individualizing simvastatin dose with respect to CYP3A4 activity
Polymorphismen in der Promoter- und Enhancerregion von CYP3A4
CYP3A4 and CYP3A5genotyping by Pyrosequencing
Cross-species variability in lobular geometry and cytochrome P450 hepatic zonation: insights into CYP1A2, CYP2D6, CYP2E1 and CYP3A4
Cross-species variability in lobular geometry and cytochrome P450 hepatic zonation : insights into CYP1A2, CYP2D6, CYP2E1 and CYP3A4
Antivirals and nuclear receptor activation of CYP3A4 and 2B6
Myricetin inhibits CYP3A4, GST, and MRP1 in hepatic cancer cells
Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1and colorectal cancer risk
Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies
CYP3A4 drug metabolism considerations in pediatric pharmacotherapy
Selective expression of KCNA5 and KCNB1 genes in gastric and colorectal carcinoma
Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel
Individualizing simvastatin dose with respect to CYP3A4 activity